Shaw-Ling Wang

Radiographic progression by Prostate Cancer Working Group (PCWG)‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer

G. Pond, M. Michaelson, G. Sonpavde, 2014, BJU international.

Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.

G. Pond, M. Michaelson, G. Sonpavde, 2012 .

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

F. Saad, M. Michaelson, J. Gschwend, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

W. Stock, D. DeAngelo, A. Advani, 2012 .

Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.

Gregory R Pond, Arnoud J Templeton, Andrew J Armstrong, 2014, Clinical genitourinary cancer.

Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS).

B. Melichar, K. Kern, J. Martini, 2019, Journal of Clinical Oncology.

Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, M. Michaelson, J. Gschwend, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.